Physician profile
Daniel A Rosloff
NPI 1770977175
$10,313.81
in general payments reported to CMS, 2019-2025
31 companies · $1,822 in 2025
The $1,822 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,068 · 2021: $1,590 · 2022: $1,803 · 2023: $2,254 · 2024: $1,775 · 2025: $1,822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,835 · Consulting Fee: $16.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,834.77 |
| Consulting Fee | $16.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $972.48 | 2021-2025 | Orladeyo |
| Glaxosmithkline, LLC. | $919.97 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pharming Healthcare, INC. | $890.00 | 2020-2025 | Ruconest |
| Csl Behring | $883.24 | 2020-2025 | Haegarda, Hizentra, Andembry |
| Astrazeneca Pharmaceuticals LP | $825.31 | 2020-2025 | Tezspire, Fasenra, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $817.35 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Octapharma USA, INC. | $808.37 | 2020-2024 | Panzyga, Cutaquig |
| Novartis Pharmaceuticals Corporation | $717.72 | 2022-2025 | |
| Pfizer INC. | $517.72 | 2020-2025 | |
| Genentech USA, INC. | $451.55 | 2021-2025 | Xolair |
| Amgen INC. | $439.72 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $390.81 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $345.66 | 2021-2025 | Xembify, Gamunex-C |
| Genzyme Corporation | $139.52 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.43 | 2022-2025 | Spevigo, Spiriva Respimat |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $130.15 | 2022 | |
| Kaleo, INC. | $125.34 | 2021-2024 | Auvi-Q |
| Optinose US, INC. | $121.35 | 2020-2023 | |
| Adma Biomanufacturing LLC | $113.71 | 2020-2023 | |
| Teva Pharmaceuticals USA, INC. | $101.90 | 2021-2023 | Airduo Digihaler |
| Abbvie INC. | $79.09 | 2022-2025 | |
| Incyte Corporation | $70.38 | 2021-2023 | Opzelura |
| Horizon Therapeutics Plc | $68.20 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $59.89 | 2023-2024 | Ryaltris |
| Invivyd INC | $45.81 | 2025 | Pemgarda |
| Alk-Abello, INC | $34.53 | 2022-2023 | Grastek, Ragwitek, Odactra |
| Ars Pharmaceuticals Operations, INC. | $29.59 | 2025 | Neffy |
| Cycle Pharmaceuticals INC | $23.34 | 2025 | Sajazir |
| Blueprint Medicines Corporation | $21.44 | 2024 | Ayvakit |
| Galderma Laboratories, L.P. | $19.70 | 2025 | Nemluvio |
| Lilly USA, LLC | $15.54 | 2024 | Ebglyss, Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rosloff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.